Harrow Health, Inc. (HROW)

NASDAQ: HROW · IEX Real-Time Price · USD
12.75
+0.02 (0.16%)
Mar 28, 2024, 11:40 AM EDT - Market open

Company Description

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.

The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.

In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop.

The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023.

Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Harrow Health, Inc.
Harrow Health logo
Country United States
Founded 1998
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 315
CEO Mark L. Baum J.D.

Contact Details

Address:
102 Woodmont Blvd, Suite 610
Nashville, Tennessee 37215
United States
Phone 615.733.4731
Website harrowinc.com

Stock Details

Ticker Symbol HROW
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001360214
CUSIP Number 415858109
ISIN Number US4158581094
Employer ID 45-0567010
SIC Code 2834

Key Executives

Name Position
Mark L. Baum J.D. Chief Executive Officer and Chairman of the Board
Andrew R. Boll C.F.A., C.M.A. Chief Financial Officer and Corporate Secretary
John P. Saharek MBA Chief Commercial Officer
Dr. Dennis E Saadeh Pharm.D. Chief Scientific Officer
Jamie Webb Director of Communications and Investor Relations
Kim Barratt Chief of Staff
Dr. Mark A. Mannebach Ph.D., R.Ph. Head of Regulatory Affairs and Pharmacovigilance

Latest SEC Filings

Date Type Title
Mar 21, 2024 8-K Current Report
Mar 20, 2024 8-K Current Report
Mar 19, 2024 8-K Current Report
Mar 19, 2024 10-K Annual Report
Feb 15, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 29, 2024 8-K Current Report
Jan 29, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals